A multifunctional theranostic agent based on rhodamine-modified copper-gallic acid nanoparticles targeting Alzheimer’s β‑amyloid species DOI
Luqi Liu, Wei Liu, Xiaoyan Dong

et al.

Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 163063 - 163063

Published: April 1, 2025

Language: Английский

Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives DOI Creative Commons
Virendra Kumar Yadav, Seshathiri Dhanasekaran, Nisha Choudhary

et al.

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: Jan. 22, 2025

Parkinson’s disease is a progressive neurodegenerative that destroys substantia nigra dopaminergic neurons, causing tremors, bradykinesia, rigidity, and postural instability. Current treatment approaches primarily focus on symptom management, employing pharmacological, non-pharmacological, surgical methods. However, these treatments often result in fluctuating symptoms, side effects, progression. Here, the authors have reviewed emerging field of nanomedicine as promising path for treatment, emphasizing its potential to overcome limitations traditional therapies. Nanomedicine utilizes nanoparticles targeted drug delivery, leveraging their small size high surface area volume ratio cross blood-brain barrier deliver therapeutic agents directly affected brain regions. Various nanoparticles, including lipid-based, polymeric, metallic, carbon-based, shown treatment. Additionally, nanocarrier systems like liposomes, nanogels, dendrimers, solid lipid offer controlled sustained release agents, enhancing bioavailability reducing effects. This review provides insights into pathophysiology disease, highlighting mechanisms neurodegeneration, role alpha-synuclein, disruption pathways. It further discusses application gene therapy conjunction with interventions.

Language: Английский

Citations

2
Paclitaxel prodrug nanoparticles boost antitumor efficacy via hitchhiking of human serum albumin DOI

Shaojin Lu,

Shiyu Zhou,

Xiujuan Xiang

et al.

Journal of Colloid and Interface Science, Journal Year: 2024, Volume and Issue: 679, P. 144 - 154

Published: Oct. 16, 2024

Language: Английский

Citations

4
Nanoscale drug formulations for the treatment of Alzheimer's disease progression DOI Creative Commons

Liu Liqin,

Haini He,

Bert N. La Du

et al.

RSC Advances, Journal Year: 2025, Volume and Issue: 15(6), P. 4031 - 4078

Published: Jan. 1, 2025

Alzheimer's disease (AD) is a devastating neurodegenerative disorder with no effective disease-modifying treatments.

Language: Английский

Citations

0
ROS-related nanoparticles for the management of Alzheimer’s disease: Wielding the double-edged sword DOI

Yibin Yu,

Qi Zhang, Yihao Guo

et al.

Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 161784 - 161784

Published: March 1, 2025

Language: Английский

Citations

0
A multifunctional theranostic agent based on rhodamine-modified copper-gallic acid nanoparticles targeting Alzheimer’s β‑amyloid species DOI
Luqi Liu, Wei Liu, Xiaoyan Dong

et al.

Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 163063 - 163063

Published: April 1, 2025

Language: Английский

Citations

0